arrow
M

Maria Tsoli

children's cancer institute
H指数:27
被引数:3,603

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Precision-guided therapy in H3K27-altered diffuse midline glioma

H3K27-改变的弥漫性中线胶质瘤中的精准导向疗法

2026-05-190
OAAI
Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma

联合抑制FACT和BET破坏转录以抑制弥漫性中线胶质瘤小鼠模型的肿瘤生长

2026-01-140
PRE
The development of ACT001 with Mcl-1 inhibitors as a novel combination therapy for the treatment of paediatric diffuse midline glioma

ACT001与Mcl-1抑制剂联合开发作为一种新型联合疗法,用于治疗儿童弥漫性中线胶质瘤

2025-11-010
OAAI
CHROMATIN REMODELING WITH COMBINED FACT AND BET INHIBITION DISRUPTS ONCOGENIC TRANSCRIPTION IN DIFFUSE MIDLINE GLIOMA

联合FACT和BET抑制的染色质重塑破坏弥漫性中线胶质瘤中的致癌转录

2025-11-010
OAAI
Combination of ALK2 and cholesterol targeting agents exploits linked genetic and metabolic dependencies in diffuse midline glioma

ALK2与胆固醇靶向剂的组合利用弥漫性中线胶质瘤中相互关联的遗传和代谢依赖性

2025-11-010
OAAI
Germline analysis of an international cohort of pediatric diffuse midline glioma patients

对国际队列儿童弥漫性中线胶质瘤患者的生殖系分析

2025-03-120
PRE
High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic

高通量体外药物筛选和体内研究将fenretinide确定为一种能够穿透血脑屏障的DMG治疗药物。

2025-02-120
PRE
PEDIATRIC PATIENTS WITH DIFFUSE MIDLINE GLIOMA DEMONSTRATE AN UNEXPECTED PREVALENCE OF GERMLINE VARIANTS IN HOMOLOGOUS RECOMBINATION GENES

弥漫性中线胶质瘤的儿科患者在同源重组基因中表现出意想不到的种系变异患病率

2024-06-180
OAAI
PRECISION GUIDED THERAPY PROVIDES CLINICAL BENEFIT IN H3K27-ALTERED DIFFUSE MIDLINE GLIOMA
2024-06-180
OAAI
A comprehensive approach: Copper chelation therapy modulates epigenetic, kinase signaling and metabolic pathways in diffuse midline gliomas (DMG)
2024-03-220
PRE